The HI-STAR study: Resource utilization and costs associated with serologic testing for antibody-positive patients at four United States medical centers

Peter Mazonson, Molly Efrusy, Chris Santas, Alyssa Ziman, James Burner, Susan Roseff, Arthi Vijayaraghavan, Richard Kaufman

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background Little is known about how the resource utilization and costs of serologic work ups for positive antibody screens vary across subpopulations based on diagnosis, transfusion history, and serologic testing history. Study Design and Methods Detailed data were collected on patient demographics, diagnoses, transfusion history, history of known allo-and autoantibodies, and specific serologic tests performed for 6077 consecutive serologic work ups in 3608 antibody-positive patients between 2009 and 2011 at four US academic medical centers. Direct testing costs were also determined at each site for each serologic test performed to calculate total costs per work up and per patient over the duration of the study. Results The mean direct cost of serologic testing was $114 per work up and $195 per patient. The mean cost per patient was significantly higher for 12 of 19 diagnostic categories evaluated, including autoimmune hemolytic anemia (mean cost per patient, $1490; p < 0.001), hematologic malignancies ($640, p < 0.001), and transplant recipients ($462, p = 0.019). Patient transfusion and serologic testing characteristics associated with greatest increases in costs included history of a warm autoantibody ($626, p < 0.001) and more than five prior transfusions ($404, p < 0.001). Conclusion Antibody-positive patients with complex diagnoses or transfusion histories require significantly more resources and incur greater cost to assess red blood cell antibody status.

Original languageEnglish (US)
Pages (from-to)271-277
Number of pages7
JournalTransfusion
Volume54
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Costs and Cost Analysis
Antibodies
History
Serologic Tests
Autoantibodies
Autoimmune Hemolytic Anemia
Hematologic Neoplasms
Erythrocytes
Demography

ASJC Scopus subject areas

  • Hematology
  • Immunology
  • Immunology and Allergy

Cite this

The HI-STAR study : Resource utilization and costs associated with serologic testing for antibody-positive patients at four United States medical centers. / Mazonson, Peter; Efrusy, Molly; Santas, Chris; Ziman, Alyssa; Burner, James; Roseff, Susan; Vijayaraghavan, Arthi; Kaufman, Richard.

In: Transfusion, Vol. 54, No. 2, 02.2014, p. 271-277.

Research output: Contribution to journalArticle

Mazonson, Peter ; Efrusy, Molly ; Santas, Chris ; Ziman, Alyssa ; Burner, James ; Roseff, Susan ; Vijayaraghavan, Arthi ; Kaufman, Richard. / The HI-STAR study : Resource utilization and costs associated with serologic testing for antibody-positive patients at four United States medical centers. In: Transfusion. 2014 ; Vol. 54, No. 2. pp. 271-277.
@article{92ea2c32af944876a54bc95743add777,
title = "The HI-STAR study: Resource utilization and costs associated with serologic testing for antibody-positive patients at four United States medical centers",
abstract = "Background Little is known about how the resource utilization and costs of serologic work ups for positive antibody screens vary across subpopulations based on diagnosis, transfusion history, and serologic testing history. Study Design and Methods Detailed data were collected on patient demographics, diagnoses, transfusion history, history of known allo-and autoantibodies, and specific serologic tests performed for 6077 consecutive serologic work ups in 3608 antibody-positive patients between 2009 and 2011 at four US academic medical centers. Direct testing costs were also determined at each site for each serologic test performed to calculate total costs per work up and per patient over the duration of the study. Results The mean direct cost of serologic testing was $114 per work up and $195 per patient. The mean cost per patient was significantly higher for 12 of 19 diagnostic categories evaluated, including autoimmune hemolytic anemia (mean cost per patient, $1490; p < 0.001), hematologic malignancies ($640, p < 0.001), and transplant recipients ($462, p = 0.019). Patient transfusion and serologic testing characteristics associated with greatest increases in costs included history of a warm autoantibody ($626, p < 0.001) and more than five prior transfusions ($404, p < 0.001). Conclusion Antibody-positive patients with complex diagnoses or transfusion histories require significantly more resources and incur greater cost to assess red blood cell antibody status.",
author = "Peter Mazonson and Molly Efrusy and Chris Santas and Alyssa Ziman and James Burner and Susan Roseff and Arthi Vijayaraghavan and Richard Kaufman",
year = "2014",
month = "2",
doi = "10.1111/trf.12176",
language = "English (US)",
volume = "54",
pages = "271--277",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The HI-STAR study

T2 - Resource utilization and costs associated with serologic testing for antibody-positive patients at four United States medical centers

AU - Mazonson, Peter

AU - Efrusy, Molly

AU - Santas, Chris

AU - Ziman, Alyssa

AU - Burner, James

AU - Roseff, Susan

AU - Vijayaraghavan, Arthi

AU - Kaufman, Richard

PY - 2014/2

Y1 - 2014/2

N2 - Background Little is known about how the resource utilization and costs of serologic work ups for positive antibody screens vary across subpopulations based on diagnosis, transfusion history, and serologic testing history. Study Design and Methods Detailed data were collected on patient demographics, diagnoses, transfusion history, history of known allo-and autoantibodies, and specific serologic tests performed for 6077 consecutive serologic work ups in 3608 antibody-positive patients between 2009 and 2011 at four US academic medical centers. Direct testing costs were also determined at each site for each serologic test performed to calculate total costs per work up and per patient over the duration of the study. Results The mean direct cost of serologic testing was $114 per work up and $195 per patient. The mean cost per patient was significantly higher for 12 of 19 diagnostic categories evaluated, including autoimmune hemolytic anemia (mean cost per patient, $1490; p < 0.001), hematologic malignancies ($640, p < 0.001), and transplant recipients ($462, p = 0.019). Patient transfusion and serologic testing characteristics associated with greatest increases in costs included history of a warm autoantibody ($626, p < 0.001) and more than five prior transfusions ($404, p < 0.001). Conclusion Antibody-positive patients with complex diagnoses or transfusion histories require significantly more resources and incur greater cost to assess red blood cell antibody status.

AB - Background Little is known about how the resource utilization and costs of serologic work ups for positive antibody screens vary across subpopulations based on diagnosis, transfusion history, and serologic testing history. Study Design and Methods Detailed data were collected on patient demographics, diagnoses, transfusion history, history of known allo-and autoantibodies, and specific serologic tests performed for 6077 consecutive serologic work ups in 3608 antibody-positive patients between 2009 and 2011 at four US academic medical centers. Direct testing costs were also determined at each site for each serologic test performed to calculate total costs per work up and per patient over the duration of the study. Results The mean direct cost of serologic testing was $114 per work up and $195 per patient. The mean cost per patient was significantly higher for 12 of 19 diagnostic categories evaluated, including autoimmune hemolytic anemia (mean cost per patient, $1490; p < 0.001), hematologic malignancies ($640, p < 0.001), and transplant recipients ($462, p = 0.019). Patient transfusion and serologic testing characteristics associated with greatest increases in costs included history of a warm autoantibody ($626, p < 0.001) and more than five prior transfusions ($404, p < 0.001). Conclusion Antibody-positive patients with complex diagnoses or transfusion histories require significantly more resources and incur greater cost to assess red blood cell antibody status.

UR - http://www.scopus.com/inward/record.url?scp=84893979984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893979984&partnerID=8YFLogxK

U2 - 10.1111/trf.12176

DO - 10.1111/trf.12176

M3 - Article

C2 - 23550807

AN - SCOPUS:84893979984

VL - 54

SP - 271

EP - 277

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 2

ER -